story of the week
Neratinib After Trastuzumab-Based Adjuvant Therapy Improves Invasive DFS in HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neratinib After Trastuzumab-Based Adjuvant Therapy in HER2-Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2017 Nov 13;[EPub Ahead of Print], M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, G von Minckwitz, SKL Chia, J Mansi, CH Barrios, M Gnant, Z Tomašević, N Denduluri, R Šeparović, E Gokmen, A Bashford, M Ruiz Borrego, SB Kim, EH Jakobsen, A Ciceniene, K Inoue, F Overkamp, JB Heijns, AC Armstrong, JS Link, AA Joy, R Bryce, A Wong, S Moran, B Yao, F Xu, A Auerbach, M Buyse, A ChanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.